The adoptive transfer of tumor-reactive CD8+ T cells into tumor-bearing hosts provides an
attractive alternative to vaccination-based active immunotherapy of melanoma. The …

Immunotherapy of cancer is often performed with altered “analog” peptide Ags optimized for
HLA class I binding, resulting in enhanced immunogenicity, but the induced T cell responses …

Cytolytic and helper T cells recognize small peptide fragments of protein antigens that are
intracellularly processed and delivered to the cell surface in conjunction with HLA …

In a recent clinical trial, HLA-A2+ melanoma patients were vaccinated with a peptide derived
from the melanoma Ag gp100, which had been modified at the second position (g9-209 2M) …

CD8+ T cells have the potential to attack and eradicate cancer cells. The efficacy of
therapeutic vaccines against cancer, however, lacks defined immune correlates of tumor …

A phase I clinical trial of a vaccine consisting of synthetic melanoma peptide-pulsed DC
(UPCI 95-060) has recently been completed at the University of Pittsburgh Cancer Institute …

HLA-A* 0201 melanoma patients often develop a CTL response to an immunodominant
peptide derived from the melanocyte lineage-specific protein Melan-A/MART-1. We have …

Adoptive cell transfer (ACT) of in vitro expanded autologous tumor-infiltrating lymphocytes
(TIL) has been shown to exert therapeutic efficacy in melanoma patients. We aimed to …

Background: Monitoring the immune response to epitope-specific vaccination in cancer
patients is important for vaccine development. The traditional method, in which the in vitro …

In the present report, we have studied the potential of naive and activated effector CD8+ T
cells to function as anti-tumor T cells to a solid tumor using OVA-specific T cells from TCR …